Aldo Naselli1, Federica Penco1, Luca Cantarini1, Antonella Insalaco1, Mariolina Alessio1, Alberto Tommasini1, Cristina Maggio1, Laura Obici1, Romina Gallizi1, Marco Cimmino1, Sara Signa1, Orso Maria Lucherini1, Sonia Carta1, Francesco Caroli1, Alberto Martini1, Anna Rubartelli1, Isabella Ceccherini1, Marco Gattorno1. 1. From the Unità Operativa (UO) Pediatria 2, IRCCS G. Gaslini; Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova; Laboratorio di Biologia Cellulare, IRCCS Azienda Ospedaliera Universitaria (AOU) San Martino Istituto Scientifico Tumori (IST); Unità Operativa Complessa (UOC) Genetica Medica, IRCCS G. Gaslini; Università degli Studi di Genova, Genoa; Dipartimento di Reumatologia, Policlinico Le Scotte, Università di Siena, UO Reumatologia, Siena; Ospedale Bambino Gesù, Rome; Dipartimento di Pediatria, Ospedale Federico II, Naples; Dipartimento di Pediatria, IRCCS Burlo Garofalo, Trieste; Dipartimento di Scienze per la Promozione della Salute e Materno Infantile "G. D'Alessandro", Palermo; Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo, Pavia; Dipartimento Materno-Infantile, Ospedale Gaetano-Martino, Messina, Italy.A. Naselli*, MD, UO Pediatria 2, IRCCS G. Gaslini; F. Penco*, MD, UO Pediatria 2, IRCCS G. Gaslini; L. Cantarini, MD, Dipartimento di Reumatologia, Policlinico Le Scotte, Università di Siena, UO Reumatologia; A. Insalaco, MD, Ospedale Bambino Gesù; M. Alessio, MD, Dipartimento di Pediatria, Ospedale Federico II; A. Tommasini, MD, Dipartimento di Pediatria, IRCCS Burlo Garofalo; C. Maggio, MD, Dipartimento di Scienze per la Promozione della Salute e Materno Infantile "G. D'Alessandro"; L. Obici, MD, Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo; R. Gallizi, MD, Dipartimento Materno-Infantile, Ospedale Gaetano-Martino; M. Cimmino, MD, Clinica Reumatologica, Dipartimento di Medicina Interna, Università di Genova; S. Signa, MD, UO Pediatria 2, IRCCS G. Gaslini; O.M. Lucherini, MD, Dipartimento di Reumatologia, Policlinico Le Scotte, Università di Siena, UO Reumatologia; S. Carta, MD, Laboratorio di Biologia Cellulare, IRCCS AOU San Martino IST; F. Caroli, MD, UOC Genetica Medica, IRCCS G. Gaslini; A. Martini, MD, UO Pediatri
Abstract
OBJECTIVE: The aim of our study was to analyze the clinical and functional effect of the p.Q703K (p. Q705K, c. 2107C>A) variant of the NLRP3 gene in a population of patients screened for suspected cryopyrin-associated periodic syndrome (CAPS). METHODS: Since 2002, 580 patients underwent molecular analysis for NLRP3. Data on clinical presentation, response to treatment, and longterm followup were collected using a uniform questionnaire. The pattern of cytokine secretion after lipopolysaccharide stimulation from isolated monocytes was analyzed in 3 patients carrying the p.Q703K variant and 1 patient with a chronic infantile neurologic, cutaneous, articular syndrome phenotype carrying both the p.M406I and p.Q703K, and compared with 7 patients with CAPS with sure pathogenic variants and 6 healthy controls. RESULTS: The p.Q703K variant was found in 57 screened patients with an overall allelic frequency of 5%. The frequency in normal controls was 5.5%. Clinical data at the moment of molecular analysis and at followup were available in 36 patients. Two patients displayed additional mutations of NLRP3. The mean followup was 2.5 years. Thirteen patients (39%) had a final diagnosis different from the original suspicion of CAPS. The remaining 21 patients displayed a mild phenotype mainly characterized by recurrent episodes of urticarial rash and arthralgia. Only 8 patients were treated with anti-interleukin (IL)-1 treatment, with a complete response in 5 patients. The pattern of secretion of IL-1β and other cytokines (IL-6 and IL-1 receptor antagonist) in patients did not display the aberrancies observed in patients with CAPS and was similar to that observed in healthy controls. CONCLUSION: The present study confirms the weak clinical and functional effect of the p.Q703K variant.
OBJECTIVE: The aim of our study was to analyze the clinical and functional effect of the p.Q703K (p. Q705K, c. 2107C>A) variant of the NLRP3 gene in a population of patients screened for suspected cryopyrin-associated periodic syndrome (CAPS). METHODS: Since 2002, 580 patients underwent molecular analysis for NLRP3. Data on clinical presentation, response to treatment, and longterm followup were collected using a uniform questionnaire. The pattern of cytokine secretion after lipopolysaccharide stimulation from isolated monocytes was analyzed in 3 patients carrying the p.Q703K variant and 1 patient with a chronic infantile neurologic, cutaneous, articular syndrome phenotype carrying both the p.M406I and p.Q703K, and compared with 7 patients with CAPS with sure pathogenic variants and 6 healthy controls. RESULTS: The p.Q703K variant was found in 57 screened patients with an overall allelic frequency of 5%. The frequency in normal controls was 5.5%. Clinical data at the moment of molecular analysis and at followup were available in 36 patients. Two patients displayed additional mutations of NLRP3. The mean followup was 2.5 years. Thirteen patients (39%) had a final diagnosis different from the original suspicion of CAPS. The remaining 21 patients displayed a mild phenotype mainly characterized by recurrent episodes of urticarial rash and arthralgia. Only 8 patients were treated with anti-interleukin (IL)-1 treatment, with a complete response in 5 patients. The pattern of secretion of IL-1β and other cytokines (IL-6 and IL-1 receptor antagonist) in patients did not display the aberrancies observed in patients with CAPS and was similar to that observed in healthy controls. CONCLUSION: The present study confirms the weak clinical and functional effect of the p.Q703K variant.
Authors: Kate F Kernan; Lina Ghaloul-Gonzalez; Bita Shakoory; John A Kellum; Derek C Angus; Joseph A Carcillo Journal: Genes Immun Date: 2018-07-06 Impact factor: 2.676
Authors: Jasmin Beate Kuemmerle-Deschner; Raju Gautam; Aneesh Thomas George; Syed Raza; Kathleen Graham Lomax; Peter Hur Journal: RMD Open Date: 2020-07
Authors: Susanne M Benseler; Jasmin B Kuemmerle-Deschner; Tatjana Welzel; Anna L Wildermuth; Norbert Deschner Journal: Pediatr Rheumatol Online J Date: 2021-09-14 Impact factor: 3.054